• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Generation Bio Co.

    4/23/25 4:11:43 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    DEFA14A 1 gbio-20250418xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.    )


    ​

    ​

    ​

    ​

    ​

    Filed by the

     

    Filed by a Party other than the

     

    Registrant  ☒

    ​

    Registrant  ☐

    ​

    ​

    Check the appropriate box:

    ​

    ​

    ​

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material under §240.14a-12

    ​

    GENERATION BIO CO.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ​

    ​

    ​

    ​

    ☒

    No fee required.

     

     

    ☐

    Fee paid previously with preliminary materials.

     

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

    ​


    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V72057-P26337 GENERATION BIO CO. 301 BINNEY STREET CAMBRIDGE, MA 02142 GENERATION BIO CO. 2025 Annual Meeting Vote by June 3, 2025 11:59 PM ET You invested in GENERATION BIO CO. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2025. Vote Virtually at the Meeting* June 4, 2025 9:00 AM, ET Virtually at: www.virtualshareholdermeeting.com/GBIO2025 Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V72058-P26337 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders. For Nominees: 01) Ron Cooper 02) Anthony Quinn, M.B. Ch.B., Ph.D. 03) Jason Rhodes 2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers. For 4. Adoption and approval of an amendment to our restated certificate of incorporation to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-10 and not greater than 1-for-30, without reducing the authorized number of shares of our common stock, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our board of directors, without further approval or authorization of our stockholders. For NOTE: In their discretion, the proxyholders are authorized to vote upon such other business as may properly come before the meeting and any adjournment or postponement thereof.

    Get the next $GBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    8/13/2025$7.00Outperform → Neutral
    Wedbush
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    1/14/25 4:05:17 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/11/23 4:30:19 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/6/23 4:30:13 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.

    SCHEDULE 13G/A - Generation Bio Co. (0001733294) (Subject)

    8/14/25 1:07:20 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Generation Bio Co.

    10-Q - Generation Bio Co. (0001733294) (Filer)

    8/12/25 4:15:52 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Generation Bio Co. (0001733294) (Filer)

    8/12/25 4:10:08 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Paone Antoinette covered exercise/tax liability with 468 shares and converted options into 1,592 shares, increasing direct ownership by 3% to 35,465 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    7/17/25 4:10:10 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Howze Yalonda converted options into 3,347 shares and covered exercise/tax liability with 983 shares, increasing direct ownership by 13% to 21,101 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    7/17/25 4:10:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Conway Kevin John converted options into 587 shares and covered exercise/tax liability with 173 shares, increasing direct ownership by 2% to 18,273 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    7/17/25 4:10:12 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

    • New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell-driven autoimmune diseases • Company is evaluating strategic alternatives to maximize value of its delivery system and potential therapeutics for T cell-driven autoimmune diseases for shareholders • Cash balance of $141.4M as of June 30, 2025 • Recent litigation settlement extinguishes lease liability CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's p

    8/12/25 4:05:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Announces 1-for-10 Reverse Stock Split

    CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-shar

    7/18/25 8:35:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company's 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee's entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received non-statutory stock options stock options to purchase an aggregate of 128,600 shares of the company's common stock. The options have an exercise price of $0.32 per share, wh

    7/7/25 4:05:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Generation Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Generation Bio from Outperform to Neutral and set a new price target of $7.00

    8/13/25 8:02:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by TD Cowen

    TD Cowen downgraded Generation Bio from Outperform to Market Perform

    10/19/23 7:43:32 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Generation Bio with a new price target

    Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00

    11/8/22 6:17:49 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    11/14/24 1:22:38 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    2/14/24 10:03:03 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

    Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

    2/6/25 5:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

    Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea

    5/10/23 4:15:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

    CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th

    4/5/23 7:30:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care